Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States

NCT06101329 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06101329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06101329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 17, 2023
Completion date
January 31, 2028
Enrollment
253 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pre-exposure prophylaxis of hiv infection